Although rare, loss-of-function mutations in the cadherin superfamily member FAT1 [95] have also been associated with CDK4/6is resistance, potentially due to CDK6 overexpression in ER+ breast cancer patients [80]. Here, CDK4 is linked to breast carcinoma.